Literature DB >> 24331361

Mitochondrial dysfunction in demyelinating diseases.

Karen S Carvalho1.   

Abstract

Dysfunction of the mitochondrial (mt) system is thought to play an important role in the mechanism of progression of various neurodegenerative disorders, including demyelinating disorders. They are characterized by neuroinflammation, ultimately leading to neurodegeneration. Mitochondria (mt) dysfunction is closely related to the mechanism of neuroinflammation, causing increased production of reactive oxygen species, which is detrimental to neurons and glia. Vice versa, neuroinflammation is increasingly recognized to produce mt failure, which then contributes to further neuronal injury and degeneration. Multiple sclerosis and X-linked adrenoleukodystrophy are examples of neurodemyelinating diseases that despite having a diverse etiology have in common a progressive course and significant neuroinflammation and neurodegeneration, leading to severe neurologic disability. The scientific community has become increasingly interested in how mt dysfunction relates to neuroinflammation and demyelination and what role it may play in the natural history of progressive demyelinating diseases. Research studies investigating how mt failure contributes to the progression of these conditions are emerging. A better understanding of the role of oxidative stress in progressive inflammatory demyelinating diseases might generate new potential neuroprotective therapeutic approaches for these devastating neurologic conditions.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24331361     DOI: 10.1016/j.spen.2013.09.001

Source DB:  PubMed          Journal:  Semin Pediatr Neurol        ISSN: 1071-9091            Impact factor:   1.636


  14 in total

Review 1.  SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.

Authors:  Vamshi K C Nimmagadda; Tapas K Makar; Krish Chandrasekaran; Avinash Rao Sagi; Jayanta Ray; James W Russell; Christopher T Bever
Journal:  J Neuroimmunol       Date:  2016-07-17       Impact factor: 3.478

Review 2.  Demyelination as a rational therapeutic target for ischemic or traumatic brain injury.

Authors:  Hong Shi; Xiaoming Hu; Rehana K Leak; Yejie Shi; Chengrui An; Jun Suenaga; Jun Chen; Yanqin Gao
Journal:  Exp Neurol       Date:  2015-03-24       Impact factor: 5.330

3.  Inhibition of Drp1 hyper-activation is protective in animal models of experimental multiple sclerosis.

Authors:  Fucheng Luo; Karl Herrup; Xin Qi; Yan Yang
Journal:  Exp Neurol       Date:  2017-02-24       Impact factor: 5.330

4.  Pattern of Altered Magnetization Transfer Rate in Alzheimer's Disease.

Authors:  Wenna Duan; Parshant Sehrawat; Tony D Zhou; James T Becker; Oscar L Lopez; H Michael Gach; Weiying Dai
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 5.  Regulation and function of elF2B in neurological and metabolic disorders.

Authors:  Filipe M Hanson; Rachel E Hodgson; Madalena I Ribeiro de Oliveira; K Elizabeth Allen; Susan Gerarda Campbell
Journal:  Biosci Rep       Date:  2022-06-30       Impact factor: 3.976

6.  Nrf2 Signaling in Sodium Azide-Treated Oligodendrocytes Restores Mitochondrial Functions.

Authors:  Annette Liessem-Schmitz; Nico Teske; Miriam Scheld; Stella Nyamoya; Adib Zendedel; Cordian Beyer; Tim Clarner; Athanassios Fragoulis
Journal:  J Mol Neurosci       Date:  2018-08-23       Impact factor: 3.444

7.  Impact of maternal cigarette smoke exposure on brain inflammation and oxidative stress in male mice offspring.

Authors:  Yik Lung Chan; Sonia Saad; Carol Pollock; Brian Oliver; Ibrahim Al-Odat; Amgad A Zaky; Nicole Jones; Hui Chen
Journal:  Sci Rep       Date:  2016-05-12       Impact factor: 4.379

Review 8.  A Review of Recent Advances in Neuroprotective Potential of 3-N-Butylphthalide and Its Derivatives.

Authors:  Idriss Ali Abdoulaye; Yi Jing Guo
Journal:  Biomed Res Int       Date:  2016-12-08       Impact factor: 3.411

9.  The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients.

Authors:  Agnieszka Morel; Elzbieta Miller; Michal Bijak; Joanna Saluk
Journal:  Mol Cell Biochem       Date:  2016-08-09       Impact factor: 3.396

10.  The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy.

Authors:  Bożena Adamczyk; Sławomir Wawrzyniak; Sławomir Kasperczyk; Monika Adamczyk-Sowa
Journal:  Oxid Med Cell Longev       Date:  2017-09-12       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.